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Abstract 
Neuroendocrine carcinoma (NEC) originating from the 
gastrointestinal hepatobiliary-pancreas is a rare, inva-
sive, and progressive disease, for which the prognosis 
is extremely poor. The patient was a 72-year-old man 
referred with complaints of jaundice. He was diagnosed 
with middle extrahepatic cholangiocarcinoma (cT4N1M0, 
cStage Ⅳ). He underwent a right hepatectomy 
combined with extrahepatic bile duct and portal vein 
resection after percutaneous transhepatic portal vein 
embolization. Microscopic examination showed a 
large-cell neuroendocrine carcinoma according to the 
WHO criteria for the clinicopathologic classification 
of gastroenteropancreatic neuroendocrine tumors. 
Currently, the patient is receiving combination chemo-
therapy with cisplatin and etoposide for postoperative 
multiple liver metastases. Although NEC is difficult to 
diagnose preoperatively, it should be considered an 
uncommon alternative diagnosis.
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Core tip: We encountered a resected case of a neuro-
endocrine carcinoma originating from the extrahepatic 
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INTRODUCTION
Currently, the 2010 World Health Organization (WHO) 
classification recommends that neuroendocrine tumors 
(NETs) be classified as NET Grade 1, NET Grade 2, 
and neuroendocrine carcinoma (NEC) Grade 3[1]. NEC 
originating from the gastrointestinal hepatobiliary-
pancreas is a very rare, invasive, and progressive 
disease for which the prognosis is extremely poor. 
We encountered a resected case of NEC originating 
from the extrahepatic bile duct. Herein, we present 
the clinicopathological features and clinical course of 
the patient with NEC of the extrahepatic bile duct and 
provide a brief review of the literature.
CASE REPORT
The patient was a 72-year-old man referred from a 
local hospital with complaints of jaundice. Laboratory 
data on admission showed elevated total bilirubin 
(T-bil), 12.2 mg/dL (normal range, 0.2-1.2 mg/dL); 
lactic acid dehydrogenase, 237 U/L (124-232 U/L); 
alkaline phosphatase, 1070 U/L (120-320 U/L); and 
γ-glutamyl transpeptidase, 899 U/L (5-55 U/L). The 
tumor markers tested were within normal limits; 
specifically, carcinoembryonic antigen (CEA), 2.8 ng/mL 
(normal range, < 5.0 ng/mL), and carbohydrate 
antigen 19-9, 916.8 U/mL (< 37 U/mL). Magnetic 
response cholangiopancreatography (MRCP) and endo-
scopic retrograde cholangiopancreatography (ERCP) 
demonstrated the presence of severe stenosis of the 
middle part of the common bile duct (CBD) (Figure 
1). The patient underwent endoscopic nasobiliary 
drainage (ENBD) with the aim of reducing jaundice. 
Abdominal computed tomography (CT) showed a 
tumor in the middle portion of the CBD and dilatation 
of the CBD and the intrahepatic bile ducts bilaterally 
(Figure 2). The tumor was suspected to have invaded 
the right hepatic artery and the portal vein. According 
to the Union Internationale Contre le Cancer (UICC) 
guidelines, the patient was diagnosed with middle 
extrahepatic cholangiocarcinoma (cT4N1M0, cStage 
Ⅳ)[2]. On the 3D reconstructed CT image, we con-
firmed the patient’s condition and simulated the 
operative procedure (Figure 3). A right hepatectomy 
combined with extrahepatic bile duct and portal vein 
resection after percutaneous transhepatic portal 
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Figure 1  Magnetic resonance cholangiopancreatography (A) and endo­
scopic retrograde cholangiopancreatography (B) of the bile duct. Severe 
stenosis of the middle common bile duct was observed (arrowhead).
A
B
Figure 2  Abdominal computed tomography images at two different 
levels are shown. A: Computed tomography (CT) showed a low-density mass 
measuring 18 mm in diameter located in the middle bile duct adjacent to the 
portal vein (arrowhead). An endoscopic nasobiliary drainage tube was observed 
in the bile duct; B: CT showed a low-density mass involving the right hepatic 
artery from the superior mesenteric artery in the middle bile duct (arrow). 
A
B
vein embolization was planned. The operation was 
successfully performed. Peritoneal lavage cytology 
demonstrated no cancer cells in the abdominal 
cavity. No microscopic invasion of the resected bile 
duct stump was observed in an intraoperative frozen 
specimen. The patient underwent a curative resection.
Pathologic findings
Macroscopically, a white, solid tumor measuring 30 mm 
× 30 mm × 25 mm was located in the middle portion of 
the CBD and cystic duct. On microscopic examination, 
tumor cells were detected in the middle CBD (Figure 4). 
The tumor cells were round or oval, hyperchromatic, 
and had an increased nucleus-to-cytoplasm ratio. Mitotic 
figures were quite frequent and were observed in 55 
cells per 10 high-power fields. Immunohistochemically, 
the tumor cells were diffusely positive for CD56, a 
membrane protein usually present in neuroendocrine 
cells. Tumor cells were positive for synaptophysin, 
which is typically expressed on the surface of neurons 
or endothelial cells. The Ki-67 labeling index was 
56.2%. These findings were consistent with large-
cell neuroendocrine carcinoma according to the 
WHO criteria for the clinicopathologic classification of 
gastroenteropancreatic NETs[1]. According to the UICC 
guidelines, the final classification of the tumor was 
T3aN1M0 Stage IIB.
Although the patient developed postoperative 
liver failure, he recovered and was discharged on 
postoperative day 51 in good condition. However, 
multiple liver metastases appeared 3 mo after the 
surgery. Currently, the patient is receiving combination 
chemotherapy with cisplatin and etoposide. He is now 
alive 7 mo after surgery.
DISCUSSION
Most extrahepatic bile duct tumors are adenocar-
cinomas, while other types of tumors are rare[3]. 
Biliary neuroendocrine carcinoma represents 0.19% 
of extrahepatic bile duct tumors[4]. Furthermore, 
NEC arising from the biliary tract is rare. NECs were 
previously classified as small-cell carcinomas (SCCs)[5]. 
We conducted a systematic literature search using 
PubMed (1985-2015) with the following keywords: 
“neuroendocrine carcinoma,” “small cell carcinoma,” 
and “biliary tract” and found only 24 reported cases 
of NEC of the extrahepatic biliary tracts, excluding the 
intrahepatic bile duct, the gallbladder, and the ampulla 
of Vater[5]. In some reports, NEC of the extrahepatic 
biliary tracts was primarily located in the middle to 
distal bile ducts. Patients underwent surgery in all of 
the 15 reported cases. The operative procedures were 
pancreaticoduodenectomy in 13 cases and extra bile 
duct resection in the remaining 2 cases.
Extrahepatic biliary SCCs have been categorized 
into two histological types: the pure and mixed 
types[6]. According to the 2010 WHO classification of 
NET, mixed adenoneuroendocrine carcinoma (MANEC) 
was also categorized in the same line as NEC. 
Previously, NETs have been considered to originate 
from enterochromaffin or Kulchitsky cells in the 
crypts of Lieberkühn, which are now believed to be of 
endodermal origin[7,8]. The biliary tract has a very small 
number of Kulchitsky cells, which explains the rarity of 
NETs at this site. 
A preoperative diagnosis of NEC of the biliary tract 
is considered very difficult. In a Japanese report, a 
regimen of preoperative chemoradiation therapy, 
curative resection and adjuvant chemotherapy was 
very effective based on the preoperative pathological 
diagnosis of NEC of the distal bile duct[9]. However, 
to our knowledge, such cases are rare. Iwasa et al[10] 
retrospectively examined the clinical data of twenty-
one patients with unresectable or recurrent poorly 
differentiated NEC arising from the hepatobiliary 
tract and pancreas and who received combination 
chemotherapy with cisplatin and etoposide as the 
first-line treatment. Although no complete responses 
were obtained, three patients had partial responses, 
resulting in an overall response rate of 14%. The 
median progression-free survival was 1.8 mo, and 
the median overall survival (OS) was 5.8 mo. The 
prognosis of NEC arising from the hepatobiliary tract 
remains very poor even with the recent therapeutic 
approaches.
Patients with biliary NETs have extremely different 
clinical outcomes according to histopathologic subtypes 
based on the WHO 2010 classification. In particular, 
as noted above, the prognosis of biliary NEC has been 
reported to be very poor. Kim et al[11] reported 20 
patients with biliary NET based on a curative resection. 
Seven of the 20 patients had NEC, and the other 
seven were diagnosed with MANEC. Six of 7 cases of 
NEC and all 7 cases of MANEC experienced recurrence, 
with a median OS of 9.6 and 12.2 mo, respectively. 
Based on data from the National Cancer Institute’s 
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Figure 3  3D reconstructed computed tomography fused with an magnetic 
resonance cholangiopancreatography image. The tumor was located in 
the middle bile duct. The tumor was suspected to have invaded the portal vein 
(arrowhead) and the right hepatic artery from the superior mesenteric artery 
(arrow). 
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Laboratory diagnosis
Laboratory data showed elevated total bilirubin, lactic acid dehydrogenase, 
alkaline phosphatase,γ-glutamyl transpeptidase, and carbohydrate antigen 
19-9.
Imaging diagnosis
Computed tomography showed a tumor in the middle portion of the common 
bile duct, and the tumor was suspected to have invaded the right hepatic artery 
and the portal vein.
Treatment
A right hepatectomy combined with extrahepatic bile duct and portal vein 
resection was performed after percutaneous transhepatic portal vein 
embolization.
Related reports
The authors found 24 reported cases of neuroendocrine carcinoma (NEC) 
of the extrahepatic biliary tracts in a PubMed systematic literature search 
(1985-2015) using the keywords “neuroendocrine carcinoma,” “small cell 
carcinoma,” and “biliary tract”.
Term explanation
Most extrahepatic bile duct tumors are adenocarcinomas, and biliary 
neuroendocrine carcinomas represent 0.19% of extrahepatic bile duct tumors.
Experiences and lessons
Although NEC is rare and difficult to diagnose preoperatively, it should be 
considered an uncommon alternative diagnosis.
Peer-review
The paper provides state-of-the art imaging and methodology and addresses 
Surveillance, Epidemiology, and End Results program 
(1973-2005), Albores-Saavedra et al[4] analyzed the 
demographics and 10-year relative survival rates of 
carcinoids and SCCs of the gallbladder and EHBD 
according to histologic type and stage. There were 
31 carcinoid tumors and 17 SCCs of the EHBD. The 
10-year survival rate was 80% for carcinoid tumors 
of the EHBD and 0% for SCC of the EHBD. Almost all 
patients with SCC in the biliary system died within 1 
year after the diagnosis.
In conclusion, NEC arising from the extrahepatic 
biliary tracts is rare and has a very high malignant 
potential with a poor prognosis. NEC is difficult to 
diagnose preoperatively, but it should be considered 
an uncommon alternative diagnosis. Although 
treatment strategies have not yet been established, a 
multidisciplinary approach may improve the prognosis 
of this highly malignant neoplasm.
COMMENTS
Case characteristics
The patient was a 72-year-old man referred with complaints of jaundice.
Clinical diagnosis
Physical examination showed jaundice.
Differential diagnosis
Primary adenocarcinoma of the extrahepatic bile duct.
A B
C
Figure 4  Histopathologic appearance of the neuroendocrine carcinoma. A: The cells were round or oval, hyperchromatic, and had an increased nucleus-to-
cytoplasm ratio (hematoxylin-eosin staining, magnification × 200); B: Immunohistochemically, tumor cells were diffusely positive for CD56, a membrane protein usually 
present in neuroendocrine cells; C: Immunohistochemically, tumor cells were positive for synaptophysin, which is typically expressed on the surface of neurons or 
endothelial cells.
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the importance of interdisciplinary approaches.
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